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ABSTRACT
We developed an ERβ binding prediction model to facilitate identification of
chemicals specifically bind ERβ or ERα together with our previously developed ERα
binding model. Decision Forest was used to train ERβ binding prediction model based
on a large set of compounds obtained from EADB. Model performance was estimated
through 1000 iterations of 5-fold cross validations. Prediction confidence was
analyzed using predictions from the cross validations. Informative chemical features
for ERβ binding were identified through analysis of the frequency data of chemical
descriptors used in the models in the 5-fold cross validations. 1000 permutations
were conducted to assess the chance correlation. The average accuracy of 5-fold cross
validations was 93.14% with a standard deviation of 0.64%. Prediction confidence
analysis indicated that the higher the prediction confidence the more accurate the
predictions. Permutation testing results revealed that the prediction model is unlikely
generated by chance. Eighteen informative descriptors were identified to be important
to ERβ binding prediction. Application of the prediction model to the data from ToxCast
project yielded very high sensitivity of 90-92%. Our results demonstrated ERβ binding
of chemicals could be accurately predicted using the developed model. Coupling
with our previously developed ERα prediction model, this model could be expected to
facilitate drug development through identification of chemicals that specifically bind
ERβ or ERα.

(iii) Ligand-binding domain (LDB) or C-terminal domain
(CTD). The NTD and LBD contain ligand responsive
transcriptional activation function 1 (AF1) and activation
function 2 (AF2) domains. The AF1 and AF2 domains
are responsible for the regulation of the transcriptional
activity of ERβ [5]. ERβ DBD and LBD had shown more
than 95% and 55% sequence similarity with ERα DBD
and LBD, respectively. The ERβ NTD is shorter than
the ERα NTD and shows a very low sequence homology
[6]. ERβ presents in both the nucleus and cytoplasm of
the normal and cancer cells while ERα which presents

INTRODUCTION
Estrogen receptor (ER) is the ligand-dependent
transcriptional factor. ER belongs to the nuclear receptor
family. ERα and ERβ are the two major isoforms reported
for ER [1–3]. The two isoforms have different functions
with various concentrations in tissues. Compared to
ERα, ERβ has wider tissue distribution [4]. ERβ has
similar structure architecture with other nuclear receptor
proteins and contains 3 distinct domains: (i) N-terminal
domain (NTD), (ii) DNA-binding domain (DBD), and
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in nuclei of benign and cancer cells. The cytoplasmic
ERβ binds with the estradiol or agonist and moves into
the nucleus to form homo-dimer and then binds with the
specific estrogen response elements (EREs) to activate the
transcription process through the interaction between the
transcriptional modulators and recruitment of the general
transcriptional machinery [7]. ERβ may act as a marker in
various types of cancers and a significant predictor in the
breast cancer treated with tamoxifen [8]. ERβ is a potential
cancer target, highly expressed in various cancers which
are reported as a negative for ERα [9]. The gene expression
of ERβ is different from ERα which plays an important role
in the breast and uterine cancers. Due to the high similarity
between the two isoforms, it is highly challenging to
design or identify compounds which specifically target
one subtype. Emerging data for ER indicates that the
identification of selective agonist or antagonist for ERβ
will help treat various cancers such as colon, breast,
prostate, and lungs with lower side effects. Hence ERβ is
considered as one of the emerging oncogene target.
Selective estrogen receptor modulator (SERM) is a
drug or small molecule that acts as an agonist or antagonist
by specifically binding to one of these two ER isoforms in
the target tissues based on its specificity. The difference in
binding activity to the two ER isoforms of a chemical is
the metric for determination of chemicals that specifically
bind for ERα or ERβ. The main mechanism of SERMs is to
alter the estrogenic activity in the target tissues specificity.
SERMs can selectively block the estrogens action in the
breast cells and activate the estrogens action in bone,
liver, and uterine cells. Hence, identification of selective
estrogenic activity compound is an important task in
drug discovery. Experimental identification of selective
estrogenic activity compound is doable but very expensive
and time consuming from a large pool of chemicals.
Hence, in silico approaches for screening potential
selective estrogenic activity compounds are in need. Some
prediction models were developed using different in silico
techniques such as pharmacophore model and molecular
docking [10, 11].
Multiple quantitative structure activity relationship
(QSAR) models have been developed for predicting ERα
binding activity using large sets of chemicals to ensure
prediction reliability [12, 13]. Previously, we developed an
ERα predictive model using the data set from Estrogenic
Activity Database (EADB) and validated the model using
a large data set from ToxCast [13]. Some QSAR models
have been developed for predicting ERβ binding activity
based on small sizes of chemicals of the particular scaffolds
that cover a small chemical space [14–22]. Many factors
affect the quality of a QSAR model, including the number
of compounds and their chemical space coverage used for
training, the algorithm used to train the model, and the
method for validation of the model. More reliable QSAR
models for ERβ binding activity need to be developed using
large sets of diverse chemicals covering a large chemical
www.impactjournals.com/oncotarget

space. Hence, in this study, we developed a QSAR model
for predicting ERβ binding activity using large sets of
chemicals which covers a wide range of chemical space.
DF (Decision Forest) algorithm [23–25] was used for
development of the ERβ binding activity prediction model.
The large set of chemicals and their ERβ binding activity
data were collected from EADB [26, 27] and used to train
the QSAR model. The compounds from the ToxCast data
were used as an application data set to estimate concordance
between the ERβ model predictions by traditional assay
and the high-throughput screening results. The important
molecular descriptors for ERβ binding were identified using
the cross validations. Prediction confidence was analyzed to
provide an additional metric for application of the ERβ QSAR
model.

RESULTS
Cross validations
One thousand 5-fold cross validations were
conducted to assess the goodness and robustness of the
ERβ predictive models constructed from the training set.
The results of the cross validations were summarized in
Figure 1 (the blue bars). The average prediction accuracy,
sensitivity, and specificity values for the 1000 5-fold cross
validations were 93.1%, 93.6%, and 55.2%, respectively,
indicating the ERβ predictive models performed well.
Moreover, the standard deviations of prediction accuracy,
sensitivity, and specificity in the 1000 cross validations
were 0.6%, 0.7%, and 6.1%, respectively. The small
fluctuation in the performance of the models in the
cross validations demonstrated the robustness of the ERβ
predictive models generated in the cross validations. Not
surprisingly, the average specificity was low because
much fewer ERβ non-binders than binders were included
in the training data set. It is expected that specificity could
be improved when more ERβ non-binders were identified
for training the model.

Permutation tests
The same performance metrics (prediction accuracy,
sensitivity, and specificity) were calculated for the ERβ
prediction models constructed in the 1000 permutation
tests and were plotted as the red bars in Figure 1. The
predictive accuracy, sensitivity, specificity, MCC, and
balanced accuracy values for the 1000 permutation
tests were 84.2%, 85.0%, 15.1%, 0.0%, and 50.0%,
respectively, and their corresponding standard deviations
were 1.5%, 1.5%, 6.5%, 2.0%, and 3.2%, respectively. The
0.0% MCC and 50.0% balanced accuracy obtained from
the permutations matched the expectation for modeling
random data sets, confirming the modeling process should
be implemented correctly. The performance comparison
between the 5-fold cross validations and permutation
92990
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tests revealed that the 5-fold cross validations much
outperformed the permutation tests, demonstrating the ERβ
predictive models constructed from the training set had a
good predictive power and were obtained unlikely solely
by chance.

models) of each descriptor in the cross validations were
calculated. These 447 molecular descriptors were then
ranked by their frequency values. The top 18 descriptors
were shown in Supplementary Table 1. Close up at the
18 descriptors revealed three physical chemical properties
(atomic polarizability, electronegative, and van der
Waals) were informative to the prediction models and
should play major roles in ERβ binding of chemicals. The
findings are consistent with our previously developed
ERα model that revealed molecular weight, van der Waals
volume, polarizability, and aromatic rings are important
for a chemical to bind ERα [13]. Comparative analysis
on structures of the two proteins showed that the binding
sites are similar for ERβ and ERα. Off the 23 residues in
the binding pockets, only two (ERβ M336 and I373 versus
ERα L384 and M421) are different (Supplementary Figure
1), confirming the similar chemical structural features
for binding of the two receptors with a subtle difference
(electronegative is important for ERβ binding and aromatic
ring is vital to ERα binding).

Prediction confidence
The confidence analysis was performed on the
predictions from the 5-fold cross validations. The
predictions near evenly distributed in the 10 prediction
confidence bins as shown by the black diamonds in
Figure 2. When the prediction confidence increased, the
performance of the corresponding predictions was also
improved (accuracy, sensitivity, and specificity were all
increased as depicted by the red, blue, and cyan circles,
respectively). It is worth to note that when prediction
confidence reached 0.8 or higher, the predictions were
extremely accurate, close to 100% (95% for specificity).
The prediction confidence analysis demonstrated that
prediction confidence could be an additional metric for
real application of the ERβ predictive model developed in
this study.

Concordance between EADB and ToxCast
The experimental data of the 21 common compounds
were compared to calculate the concordance between
ToxCast ERβ dimerization assays activity and EADB ERβ
binding activity. The 21 common compounds were all
binders in EADB. ToxCast OT_ER_ERβERβ_0480 ERβ
dimerization assay showed 15 actives and 6 inactives (Table

Informative descriptors
The 447 molecular descriptors in the training set
were used in different predictive ERβ models generated
in the 5-fold cross validations. The frequency (number of

Figure 1: Performance of the 5-fold cross validations (blue bars) and permutation tests (red bars). Standard deviations
were given on top of the bars. Performance metrics are indicated at the x-axis.
www.impactjournals.com/oncotarget
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Table 1: Comparison between EADB and ToxCast data of common compounds
OT_ER_ERβERβ_0480 Assay
EADB

Active

Inactive

Total

Binder

15

6

21

Non-binder

0

0

0

Total

15

6

21

1), while ToxCast OT_ER_ERβERβ_1440 ERβ dimerization
assay found 18 actives and 3 inactives (Table 2). If the
experimental ERβ binding assay data in EADB were used to
predict ToxCast ERβ dimerization data for the 21 common
compounds, the prediction accuracy would be 71.4% and
85.7% for ToxCast OT_ER_ERβERβ_0480 and OT_ER_
ERβERβ_1440 assays, respectively.

training data set had much less non-binders than binders, it
is expected that the model would have better prediction on
ERβ binders than non-binders (Figure 1). We examined the
performance of the model on actives in ERβ dimerization.
Of the 175 actives from OT_ER_ERβERβ_0480 assay, 162
were predicted as ERβ binders (Table 3). The sensitivity
92.6% was very comparable to the sensitivity 93.6% in
cross validations and 100% concordance for experimental
actives and binders (Table 1). Of the 150 actives from
OT_ER_ERβERβ_1440 assay, 135 were predicted as ERβ
binders (Table 4). Again, the sensitivity 90% was close
to the cross validation and experimental data comparison
(Table 2). The prediction on actives in ToxCast ERβ
dimerization assays indicated that the ERβ predictive model
trained using ERβ binding activity data from EADB could
be extrapolated well to predict actives in ERβ dimerization.
As expected, extrapolation of the model to inactives should
be very cautious as very low specificity was yield in the
applications: 21.5% and 21.0% for OT_ER_ERβERβ_0480
and OT_ER_ERβERβ_1440 assays, respectively.

Applications to ToxCast data
The 1805 compounds that were tested using ToxCast
OT_ER_ERβERβ_0480 assay and the 1800 compounds
that were tested using ToxCast OT_ER_ERβERβ_1440
assay were predicted using the ERβ binding prediction
model generated based on EADB data. Overall prediction
accuracy for ERβ dimerization activity using the model
was low, 28.4% and 26.7% for OT_ER_ERβERβ_0480 and
OT_ER_ERβERβ_1440, respectively. Prediction confidence
analysis showed that high confidence predictions performed
better than low confidence predictions (Figure 3). As the

Figure 2: Confidence analysis result. The accuracy (red circles), sensitivity (blue circles), and specificity (cyan circles) were given

at the left y-axis and the numbers of predictions were plotted as black diamonds at the right y-axis for 10 even prediction confidence bins
that were indicated at the x-axis.
www.impactjournals.com/oncotarget
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Table 2: Comparison between EADB and ToxCast data of common compounds
OT_ER_ERβERβ_1440 Assay
EADB

Active

Inactive

Total

Binder

18

3

21

Non-binder

0

0

0

Total

18

3

21

Table 3: Predictions on OT_ER_ERβERβ_0480 assay data
OT_ER_ERβERβ_0480
Prediction

Active

Inactive

Total

Binder

162

1280

1442

Non-binder

13

350

363

Total

175

1630

1805

Table 4: Predictions on OT_ER_ERβERβ_1440 assay data
OT_ER_ERβERβ_1440
Prediction

Active

Inactive

Total

Binder

135

1304

1439

Non-binder

15

346

361

Total

150

1650

1800

DISCUSSION

Multiple data points for the same compound were merged
to a single value to classify the compound as an ERβ binder
or non-binder. The training set has imbalanced distribution
of ERβ binders (98.8%) and non-binders (1.2%). The
high imbalance in samples is a challenging issue in

The training set compounds were collected from
the EADB with a well-defined end point (LogRBA)
value which covers a wide range of ERβ binding activity.

Figure 3: Result of application of the developed ERβ binding activity prediction model to the dimerization assays
(labeled at the x-axis) in ToxCast. Overall prediction accuracy (cyan) and prediction accuracy for high confidence predictions (blue)
and low confidence predictions (red) were plotted as bars.
www.impactjournals.com/oncotarget
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Figure 4: Chemical space of ERβ binders (blue circles) and non-binders (red circles).

Figure 5: Study design. Data from EADB was used as a training set. Mold2 in-house software was used to generate the molecular

descriptors for all compounds. Decision Forest (DF) classification method was used to generate ERβ predictive models. Five-fold
cross validations (red dashed boxes) were conducted 1000 times (blue dashed boxes) in cross validations (left panel and Result 1) and
permutation tests (right panel and Result 4). Based on the 5-fold cross validations, prediction confidence analysis was conducted (Result 2)
and informative descriptor were identified (Result 3). ToxCast data of 2 dimerization assays were used assess the capability of the model
(Result 6).
www.impactjournals.com/oncotarget
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machine learning. Even with the robust algorithm DF, the
performance of the developed model is expected to be
different between ERβ binders and non-binders. The analysis
of performance of the 5-fold cross validations yielded a
very high sensitivity (93.6%) and a low specificity (55.2%)
are consistent with the expectation. The permutation tests
results also confirmed that the bias to prediction on ERβ
binders because of imbalanced samples even there were no
signals in the data sets (randomly permuted samples). In
addition to the difference in numbers of ERβ binders and
non-binders, different chemical spaces covered by ERβ
binders and non-binders were observed (Figure 4). The ERβ
binders not only covered larger chemical space than nonbinders but also had much higher density in the covered
chemicals as shown in Figure 4. Much more chemical
knowledge on ERβ binders than non-binders were learned
by DF to generate the prediction model. It is not surprising
that the prediction model had much better performance on
ERβ binders than non-binders. Therefore, it is expected
that including more non-binders in the training set would
increase the chemical space of non-binders and improve
performance of the prediction model based on a more
balanced training set.
We not only demonstrated overall goodness of
the ERβ binding prediction model but also conducted
prediction confidence analysis to provide an additional

metric that can be used in real applications of the model.
The confidence analysis of the cross validation results
(Figure 2) revealed that the ERβ predictive models showed
high accuracy for the predictions with high confidence,
while the predictions with low confidence did not perform
well, especially for the predictions with confidence less
than 0.3 (Figure 2). Therefore, in real applications of
our ERβ binding activity prediction model, utilization of
predictions with low confidence should be cautious.
We applied the ERβ binding activity prediction
model to the ERβ related active data in ToxCast to assess
the capability of extrapolation of the model to other ERβ
related endpoints such as the two ERβ dimerization assays.
The application results revealed that the ERβ predictive
model trained using the binding activity data from EABD
was able to predict most of the actives from the two ERβ
dimerization assays (Tables 3 and 4). However, as expected
the ERβ predictive model did not show a good performance
for predicting inactives from two ERβ dimerization
assays. One of the reasons for the poor performance of
the ERβ predictive model on the inactive chemicals in the
dimerization assays might be due to the difference in the
assays for the training data and application data. The gene
expression modulated by ERβ is a cascade of events: ligand
binding ERβ induces ERβ dimerization, translocation of
ERβERβ dimers to the nucleus, and recognition of Estrogen

Figure 6: Data sets used in this study. Training data set was collected from EADB (left blue panel). Common data set contained 21

chemicals that had data in both ToxCast and EADB (middle of the right light brown panel). Application data sets were extracted from the
two ERβ dimerization assays data in ToxCast (the right light brown panel) and not contained in the training data set. Assay 1- OT_ER_
ERβERβ_0480 and Assay 2 – OT_ER_ERβERβ_1440. B – Binder and NB – Non-binder.
www.impactjournals.com/oncotarget
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Response Elements (EREs) on DNA. Binding assays and
dimerization assays measure a chemical activity on two
different events in the function mechanism. Therefore,
extrapolation of the developed model to prediction
of inactives from other ERβ related endpoints such as
dimerization should be very cautious. The model could be
improved by adding more inactive compounds in training to
increase chemical space for inactivs.
Comparison between the cross validations and
the applications revealed that extrapolation to ERβ
dimerization assay data yield less accurate predictions
than the cross validations, especially for the predictions
on the inactives. The reasons for that could be (i) all the
ERβ binders play a role in the dimerization of ERβ,(ii)
the EADB reported binders are not necessary to lead a
dimerization signal to be observed in the ERβ dimerization
assays, and (iii) the traditional ERβ binding assays are
different from the high-throughput screening assays.
The ERβ binding activity prediction model
was developed and its prediction performance and
extrapolation to other ERβ related endpoints data were
demonstrated. Comparison of ERβ binding activity
predicted by the model developed in this study with ERα
binding activity estimated using our previous ERα model
[13] could identify chemicals that specifically bind ERα or
ERβ, facilitating drug discovery and development.

Prediction confidence of the 5-fold cross-validation results
was analyzed. The critical molecular descriptors to ERβ
binding were identified by the analysis of their frequency
in the models during the cross validations. Predictive
power and chance correlation of the models were assessed
using permutation tests. The developed model was then
used to predict ERβ activity of chemical assayed in
ToxCast.

Data sets preparations
Training data set
The training set compounds were extracted from the
FDA’s EADB [24, 26, 27, 31, 33-36]. The ERβ binding
activity (binder or non-binder) for 2492 compounds were
determined based on their logRBA (Relative Binding
Affinity) values. The binding assays measure ERβ
binding affinity of chemicals. Most of the ERβ binding
activity data in EADB are determined using competitive
binding assays. A competitive binding assay works
by measuring how well a chemical competes with the
radiolabeled ligand for the receptor ERβ and the binding
affinity of the chemical is given as an IC50 value. For the
experiments with the same reference chemical tested, the
binding affinity IC50 values were converted into logRBA
values. A compound was assigned as an ERβ binder if its
logRBA value is equal to or greater than -5; otherwise the
compound was determined as a non-binder (Figure 6).
If a compound contains more than one logRBA value, it
was assigned as an ERβ binder or non-binder based on the
consensus. Of the 2492 training compounds, 2462 were
determined as ERβ binders and only 30 were non-binders.
The determination of ERβ binder or non-binder for the
2492 compounds was given in Supplementary Table 2.

MATERIALS AND METHODS
Study design
The study design was depicted in Figure 5. The data
sets were collected from two large data sources: EADB
[26] and ToxCast databases [28, 29]. The compounds
from EADB were used to develop the ERβ predictive
model using DF. The ERβ binding affinity data from
EADB (recorded as logarithmic value of relative binding
activity (logRBA)) were used to determine ERβ binders
or non-binders for the training compounds. The activity
values for 1812 compounds from two ERβ related assays
in the ToxCast were used to assess concordance between
EADB and ToxCast data as well as to estimate the
performance of the QSAR model for predicting ToxCast
results. The common compounds contained in both
EADB and ToxCast databases were used for assessing the
concordance. The compounds only assayed in ToxCast
were used for estimating the goodness of extrapolation
of the QSAR model to high-through screening assays.
The Mold2 software [30] was used to generate the
molecular descriptors for compounds in the training and
application sets. The generated molecular descriptors
were preprocessed to remove the less informative
descriptors. The preprocessed training data set were used
to develop the ERβ predictive model using DF [2, 23,
31–33]. Robustness of performance of the ERβ predictive
models were estimated through 5-fold cross-validations.
www.impactjournals.com/oncotarget

Application data sets
There are 1858 compounds in the ToxCast database
that were tested by ERβ dimerization assays (http://
epa.gov/ncct/toxcast/data.html, accessed on March 2,
2016) [28, 29, 37, 38] such as OT_ER_ERβERβ_0480
and OT_ER_ERβERβ_1440. These two assays use a
yellow fluorescent protein reporter that is dissected into
two fragments and fused to two ERβ to interact within
a signaling complex. The reporter is fully assembled
when ERβ dimerize. Therefore, when the ERβ molecules
are physically separated, no signal is detected; however,
when two ERβ are in close physical proximity, the two
fragments from the reporter interact to elicit a signal.
Changes in signal intensity and location are used to
measure dimerization activity of a chemical. Twentyfive compounds which do not have CAS numbers were
removed. Twenty one compounds were contained in both
the training set and ToxCast. They were used for assessing
the concordance between the ERβ binding assays in EADB
and the high-throughput screening ERβ dimerization
assays in ToxCast. After removed the 21 compounds, the
92996
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remaining compounds and their ERβ dimerization assay
data [39] from ToxCast were used as the application data
sets for estimating the extrapolation capability of the
ERβ binding activity prediction model. Among the 1812
compounds that were not included in the training set, 17
and 12 compounds were reported as not determined in
OT_ER_ERβERβ_0480 and OT_ER_ERβERβ_1440 assays,
respectively. The compounds in the application data sets
were classified as active if their AC50 values are recorded
in the ToxCast database; otherwise they were determined
as inactive. Finally, 1805 (175 binders and 1630 nonbinders) compounds for OT_ER_ERβERβ_0480 and 1800
(150 binders and 1650 non-binders) compounds for OT_
ER_ERβERβ_1440 were used in the application data sets.

contributions of independent variables by randomization that
requires a large number of such shallow trees.

Performance metrics
The performance of the ERβ predictive model can
be measured using different metrics. Prediction accuracy,
sensitivity, selectivity, Matthews’s correlation coefficient
(MCC), and balanced accuracy were used in this study.
The above mentioned metrics are computed using the
following equations:
TP + TN
Accuracy =
TP + TN + FP + FN

Mold2: Descriptor generation
Mold2
(http://www.fda.gov/ScienceResearch/
BioinformaticsTools/Mold2) software [30] was used to
generate molecular descriptors for the compounds in the
training and application sets. Compounds in the SDF files
were input into Mold2. Totally, 777 molecular descriptors
were generated for each compound. Mold2 generates onedimensional (e.g., molecular weight) and two dimensional
(e.g., structural and bond information) descriptors. The
generated molecular descriptors were pre-processed to
remove the less informative descriptors (i.e., the same
value for most of the chemicals in the training set). Out of
777 molecular descriptors, 330 descriptors are removed as
they were considered as less informative (Supplementary
Figure 2). Finally, 447 descriptors were subjected to the
DF algorithm to generate the ERβ predictive model.

TP
TP + FN

Specificity =

TN
TP + FN

MCC =

TP*TN − FP*FN

( TP + FP )( TP + FN )( TN + FP ) (TN + FN)

Balanced accuracy = (Sensitivity + Specificity) / 2
In the above equations, TP indicates true positives
(number of actual binders are predicted as binders); TN
represents true negatives (number of actual non-binders
are predicted as non-binders); FP means false positives
(number of actual non-binders are predicted as binders);
and FN is false negatives (number of actual binders are
predicted as non-binders).

Cross validation
Five-fold (5-fold) cross validations were used to
evaluate the performance of ERβ predictive models. In
a 5-fold cross validation, the training set was randomly
divided into five equal subsets. Four subsets were used to
generate a DF model and the remaining one subset was
used to test the generated DF model. This process was
repeated for each of the five subsets once and only once.
The prediction results from the five subsets were then
average to assess the prediction performance of the five
DF models. To avoid possible chance correlation in the
random division of a data set into five subsets, the 5-fold
validation was repeated for 1000 times using different
random divisions to reach a statistically reliable validation.

DF
DF is a powerful algorithm that combines multiple
decision tree models to generate a consensus predictive
model with high accuracy [23–25]. Each decision tree model
is generated using a different set of molecular descriptors.
The algorithm of DF consists of four steps. Initially, it
constructs an individual decision tree using a pool of
molecular descriptors; the molecular descriptors used in the
previously generated decision tree model are then removed
from the pool of molecular descriptors; the above two steps
are repeated until no improvement can be achieved by adding
more decision tree models; and finally, it combines all the
decision tree models to make a final predictive model. DF
is different from the Random Forests algorithm [40]. DF
uses less decision trees that are constructed using all samples
and variables. Therefore the trees are deep and accurate.
In contract, Random Forests combines a large number of
decision trees that are built using part of samples through
bootstrapping and a small fraction of variables randomly
selected. Thus, the trees are shallow and not accurate. The
diversity of decision trees that is achieved by using different
variables is the key to DF, while Random Forests ensures
www.impactjournals.com/oncotarget

Sensitivity =

Permutation test
Permutation tests were used to estimate the
predictive power of the generated models. In a permutation
test, the ERβ binding activity data in the training data
set were randomly scrambled to generate a permuted
data set. A 5-fold cross validation test was performed
on the permuted data set. The accuracy, specificity,
and sensitivity of the 5-fold cross validation test were
calculated to measure the chance correlation. To reach a
92997
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statistically reliable estimation, this process was repeated
for 1000 times to generate the 1000 permuted data sets for
running 5-fold cross validations.

balanced accuracy was calculate for the two different
ERβ dimerization assays in ToxCast relative to EADB,
where EADB was used as a primary metrics to measure
the activity data agreement between EADB and ToxCast
assays.

Prediction confidence analysis
Prediction confidence analysis was carried out
not only to classify the compounds as ERβ binder and
non-binder but also to estimate the probability of the
compounds to be an ERβ binder or non-binder. Hence,
the models were assessed based on not only the overall
prediction performance but also the relationship between
the prediction confidence levels and their performance.
The prediction confidence value was calculated using the
below equation.
P − 0.5
Confidence =
0.5
Where P represents the probability of a chemical
being an ERβ binder (0.5 <= P <=1) or non-binder (0
< P < 0.5). Prediction confidence is a value between 0
and 1. The larger the prediction confidence is, the more
confident the prediction is. To conduct confidence
analysis, the prediction confidence was calculated for each
of the predictions from the 1000 iterations of 5-fold cross
validations at first. The predictions were then put into 10
even bins based on their prediction confidence values.
Prediction performance metrics were finally calculated
for the predictions in each of the prediction confidence
bins according to their actual and predicted ERβ binding
activity.

Applications
The application data sets were used to assess the
goodness of the ERβ binding activity prediction model
in extrapolation to predicting chemicals for their highthroughput screening ERβ dimerization assays activity. The
application data sets contain 1805 and 1800 compounds
for OT_ER_ERβERβ_0480 and OT_ER_ERβERβ_1440
ERβ dimerization assays from ToxCast. The constructed
ERβ binding activity predictive model was used to predict
ERβ binders and non-binders for the chemicals in the
application data sets. The accuracy, sensitive, selectivity,
and balanced accuracy were calculated to assess the
goodness of the ERβ binding activity predictive model,
when the model was extrapolated to predicting outcome
from high-throughput screening ERβ dimerization assays.

Disclaimer
The views expressed in this manuscript do not
necessarily represent those of the U.S. Food and Drug
Administration.

CONCLUSIONS
The ERβ predictive model was developed and cross
validated using a large data set from EADB. The cross
validations demonstrated the predictive power of the ERβ
predictive model. The prediction confidence provides an
additional metric for application of the ERβ predictive
model. The important molecular descriptors linked to
the knowledge of ligand binding to ER were identified.
Applications of the developed model to ERβ dimerization
assays data in ToxCast demonstrated the capability
of extrapolation to other ERβ related endpoints data.
Combination of the model developed in this study with
our previous ERα binding activity prediction model could
help to design or identify the selective compounds for ERβ
and ERα which would be crucial in drug discovery and
safety evaluation.

Identification of informative descriptors
The importance of molecular descriptors in ERβ
binding was estimated based on the frequency distribution
of the descriptors used in the models in the 5-fold cross
validations. A frequency value in the models from 5-fold
cross validations was calculated for each of the molecular
descriptors. The molecular descriptors were then ranked
based on their frequency values. The descriptors that were
used in more than 90% of the models were finally selected
as the informative descriptors for the ERβ models.

Concordance between EADB and ToxCast
The two ERβ dimerization assays from ToxCast
reported the estrogenic activity for >1800 compounds.
Among the >1800 compounds, 21 had ERβ binding data in
EADB. The ERβ binding data in EADB and the estrogenic
activity data from high-throughput screening assays in
ToxCast (Supplementary Table 3) were compared for
the 21 common compounds to assess the correlation
between the two types of assays (traditional and highthroughput screening assays). This analysis could help to
understand how well the ERβ binding predictive model
would be applied to data from different assays. The
www.impactjournals.com/oncotarget
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